10 citations
,
September 2016 in “Journal of cutaneous medicine and surgery” In this prospective study, dabrafenib and trametinib were associated with various skin side effects, including papillomas, hyperkeratosis, and acneiform eruptions in patients with metastatic melanoma.
December 2025 in “Pediatric Dermatology” In this study, a 14-year-old girl developed Malassezia folliculitis and seborrheic dermatitis after starting trametinib, which improved with itraconazole treatment. The research underscores the importance of recognizing trametinib-related skin reactions and suggests managing them with antifungal therapy without necessarily discontinuing the medication.
133 citations
,
May 2016 in “Cell Host & Microbe” In this study, human dermal fibroblasts were identified as natural host cells that support productive Merkel cell polyomavirus infection, and the MEK antagonist trametinib was introduced as an effective inhibitor to control the virus.
32 citations
,
May 2016 in “European journal of dermatology/EJD. European journal of dermatology” In this study, researchers found that targeted therapies for metastatic melanoma often cause hair and nail side effects, with hair changes more common in patients treated with BRAF inhibitors like vemurafenib.
16 citations
,
February 2019 in “Pediatric Blood & Cancer” In this study, 96% of children with CNS tumors receiving MAPK and mTOR inhibitors experienced common, treatable skin reactions, occasionally requiring therapy adjustments.